US EditionBiogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
TORONTO, CANADA, JUL 22 – Eisai reveals four-year efficacy and safety results of lecanemab from Phase 3 Clarity AD trial and explores a subcutaneous dosing option for ongoing Alzheimer's treatment.
- Eisai Inc. said it will present four-year efficacy and safety data on lecanemab at AAIC 2025 in Toronto and virtually from July 27 to July 31.
- Since 2014, Eisai and Biogen have collaborated on development and commercialization of lecanemab, targeting amyloid-beta protofibrils believed to be the most toxic form causing neuronal injury.
- Real-World case studies from U.S. settings will be discussed on July 27, followed by four-year findings from the Phase 3 Clarity AD Open-Label Extension trial on July 30, and subcutaneous maintenance dosing data.
- According to Lynn D. Kramer, data presented at AAIC 2025 will highlight long-term findings from lecanemab's open-label extension, while Priya Singhal noted baseline characteristics from CELIA.
- Eisai Inc. has submitted applications for approval of lecanemab in 11 countries and regions, despite high development risks that limit program success.
38 Articles
38 Articles
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau …
Globe Newswire
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations...
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 - Biogen (NASDAQ:BIIB)
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations …
Several studies have demonstrated the effectiveness of certain blood tests in detecting the internal signs of the disease. A novelty that could "change the way we make the diagnosis", according to.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
